LumiThera expands Valeda research into diabetic retinopathy

LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.

The Valeda system has received a CE mark in Europe for the treatment of ocular diseases including dry age-related macular degeneration. The new studies in diabetic retinopathy will take place with the University of Wisconsin-Milwaukee.

“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with [photobiomodulation],” Janis Eells, PhD, professor, University of Wisconsin-Milwaukee, said in the release. “Our work shows that early [photobiomodulation] benefits in reducing the detrimental effects of high glucose on retinal cells, and early human data is now starting to show benefits in the clinical setting.”

LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.

The Valeda system has received a CE mark in Europe for the treatment of ocular diseases including dry age-related macular degeneration. The new studies in diabetic retinopathy will take place with the University of Wisconsin-Milwaukee.

“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with [photobiomodulation],” Janis Eells, PhD, professor, University of Wisconsin-Milwaukee, said in the release. “Our work shows that early [photobiomodulation] benefits in reducing the detrimental effects of high glucose on retinal cells, and early human data is now starting to show benefits in the clinical setting.”